Karl Eric Andersson

TL;DR: Specific evaluation, treatment guidelines, and algorithms were developed for every sexual dysfunction in men, including erectile dysfunction; disorders of libido, orgasm, and ejaculation; Peyronie's disease; and priapism.

TL;DR: Despite the efficacy of current therapies, they remain insufficient to address growing patient populations, such as those with diabetes and MetS, and increasing awareness of the adverse side effects of commonly prescribed medications on sexual function provides a rationale for developing new treatment strategies that minimize the likelihood of causing sexual dysfunction.

TL;DR: BoNTA significantly improves all symptoms and urodynamic parameters in NDO and OAB, and the effect of BoNTA in treating LUTS dysfunction appears to be overestimated in lower as opposed to higher LE studies.

TL;DR: The current definitions and diagnostic and treatment algorithms for bladder pain syndrome and chronic pelvic pain syndrome (non‐bacterial prostatitis) and future research pathways as articulated by the National Urologic Research Agenda of the American Urological Association and others are updated.

TL;DR: The absence of prolonged erections by its spontaneous intracavernous decomposition, a maximal smooth muscle relaxation by a receptor independant action and its low cost indicate its potential to become a standard drug for intracvernous pharmacotherapy.